Table 1.
Characteristics of Crohn's disease patients studied: both responders (n = 288) and nonresponders (n = 62) to infliximab.
| Responders | Nonresponders | P value | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Age | 39.6 ± 0.7 | 41.9 ± 1.5 | 0.10 | ||
| Sex | |||||
| Male | 135 | 47.4 | 26 | 41.9 | 0.44 |
| Female | 150 | 52.6 | 36 | 58.1 | |
| Years of disease | 10.2 ± 0.4 | 13.2 ± 1.1 | 0.0067 | ||
| Age at diagnosis (A) | |||||
| A1 | 36 | 12.9 | 8 | 13.1 | 0.61 |
| A2 | 203 | 72.5 | 47 | 77.1 | |
| A3 | 41 | 14.6 | 6 | 9.8 | |
| Location (L) | |||||
| L1 | 74 | 26.5 | 28 | 46.6 | 0.014a |
| L2 | 57 | 20.4 | 8 | 13.4 | |
| L3 | 137 | 49.1 | 24 | 40.0 | |
| L4 | 2 | 0.7 | 0 | 0 | |
| L1 + L4 | 3 | 1.1 | 0 | 0 | |
| L2 + L4 | 1 | 0.4 | 0 | 0 | |
| L3 + L4 | 5 | 1.8 | 0 | 0 | |
| Behavior (B) | |||||
| B1 | 79 | 28.2 | 19 | 31.7 | 0.56 |
| B2 | 27 | 9.6 | 7 | 11.7 | |
| B3 | 46 | 16.5 | 11 | 18.3 | |
| B1p | 70 | 25.0 | 8 | 13.3 | |
| B2p | 9 | 3.2 | 2 | 3.3 | |
| B3p | 49 | 17.5 | 13 | 21.7 | |
Data correspond at first IFX dose.
A1: ≤16 years; A2: 17–40 years; A3: >40 years. L1: terminal ileum; L2: colon; L3: ileocolon; L4: upper GI; L1 + L4: terminal ileum + upper GI; L2 + L4: colon + upper GI; L3 + L4: ileocolon + upper GI. B1: nonstricturing, nonpenetrating; B2: structuring; B3: penetrating; B1p: nonstricturing, nonpenetrating + perianal; B2p: structuring + perianal; B3p: penetrating + perianal.
aExcluding categories with L4.